Proposed Merger Expands Skinvisible, Inc. (SKVI) Horizons into Multi-Billion Dollar Pain Market
Company has developed and licensed novel drug delivery systems and products for over 15 years With 14 patents, Skinvisible has proven efficacy and global reach Proposed merger may transform non-opioid pain market At the cutting edge of innovative drug delivery technology since 1999, Skinvisible, Inc. (OTCQB: SKVI), in a recently announced Letter of Intent of a proposed merger with Quoin Pharmaceuticals, is now expanding its horizons into the global pain management therapeutics market. The pain management therapeutics market is projected to expand at a 3.7 percent CAGR and exceed $83 billion in the United States by 2024 (http://cnw.fm/pEyK9). Skinvisible, through…